Gelteq (NASDAQ:GELS) Releases Quarterly Earnings Results

Gelteq (NASDAQ:GELS) released its quarterly earnings results on Tuesday. The company reported ($0.12) earnings per share (EPS) for the quarter, FiscalAI reports.

Gelteq Price Performance

Shares of GELS opened at $0.66 on Thursday. Gelteq has a 1-year low of $0.39 and a 1-year high of $2.02. The firm has a fifty day moving average price of $0.63 and a 200 day moving average price of $0.76.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Gelteq from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, June 26th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Gelteq currently has an average rating of “Sell”.

Institutional Investors Weigh In On Gelteq

An institutional investor recently bought a new stake in Gelteq stock. Susquehanna International Group LLP bought a new stake in Gelteq Limited (NASDAQ:GELS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 41,550 shares of the company’s stock, valued at approximately $57,000. Susquehanna International Group LLP owned about 0.44% of Gelteq at the end of the most recent quarter.

Gelteq Company Profile

Gelteq Inc is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc is based in NEW YORK.